1. A method of treating a neurodegenerative disease involving neuroinflammation in a subject, wherein the method comprises administration of IL-33 to the subject, wherein the neurodegenerative disease involving neuroinflammation is selected from the group consisting of tauopathies, Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), spinal cord injury (SCI), and neuronal ceroid lipofuscinoses (NCL).